TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously completed the 1995 to 1996 Hepatitis B vaccination program vaccinations (Primary study) to the best of his/her knowledge and already enrolled and followed in the long term study~* Must be HBc negative~* Required standard interval between last dose of primary immunization and booster vaccination~* Written informed consent obtained from the subject~* Free of obvious health problems as established by medical history and clinical examination before entering into the study~* Previously completed routine childhood vaccination to the best of his/her knowledge~* If the subject is female, and the potential of pregnancy exists, it must be asked prior to immunization by the study nurse. According to the protocol d'immunisation du Québec, Engerix-B is not contra-indicated during pregnancy. However, if a participant thinks she could be pregnant (sexually active and no oral contraception or intra uterine device), a pregnancy test will be carried out. In case of pregnancy, the booster vaccination will be performed after delivery.~Exclusion Criteria:~- Not applicable

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening~* Active UC confirmed by endoscopy~Exclusion Criteria:~* Severe extensive colitis~* Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD~* Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etrasimod 2 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 15 to 18 months on the day of inclusion~* Informed consent form signed by the parent(s) or other legally acceptable representative~* Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures~* Child having completed all visits of the IPV25 study (NCT00604058), including the three-dose primary vaccination series with the study vaccine (IMOVAX Polio), using the route of administration as designated by randomization.~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator~* Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the trial vaccination~* Planned receipt of any vaccine during the present trial period~* Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity~* History of seizures~* History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)~* Previous fourth dose vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM injection~* Febrile illness (temperature ≥38.0 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Will receive fractional doses of IPV Intradermally
- Group B (Type: ACTIVE_COMPARATOR): Will receive full doses of IPV Intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years.~* Have chronic kidney disease per K/DOQI guidelines.~* No change in EPO status during study.~* Baseline hemoglobin of ≤ 11.0 g/dl.~Exclusion Criteria:~* Women who are pregnant or lactating.~* Received another investigational drug or device within 30 days.~* Recent parenteral or oral iron therapy.~* Patients with active GI bleeding or acute bleeding within 4 weeks.~* Patients that have other causes of anemia.~* Major surgery within 30 days or anticipated or planned major surgery during the study.~* Patients whose EPO status changes while on study.~* Patients with active infections.~* Recent blood transfusions.~* Patients with any known allergies to iron products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a mild to moderate Distal Subungual Onychomycosis (DSO) on at least 1 great toenail chosen as a Target nail~* Subjects must have maximum of 50% of nail distal edge involved~* Subjects with positive mycological results (direct microscopy and culture) of the Target nail for dermatophytes or Yeast (including Candida) at Screening~Exclusion Criteria:~* Subjects with clinically important abnormal physical findings at the Screening/Baseline visit~* Subjects with Lichen planus, eczema, psoriasis, or other abnormalities of the nail unit~* Subjects with known immunodeficiencies, radiation therapy, immune suppressive drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigator blinded Loceryl NL+ Cosmetic varnish (Type: EXPERIMENTAL): Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
- Investigator blinded Loceryl NL alone (Type: EXPERIMENTAL): Loceryl NL once/week for 12 weeks on right or left foot toenails

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of functional HoFH by either genetic or clinical criteria as defined in the protocol~2. LDL-C \>130 mg/dL at the screening visit~3. Body weight ≥15 kg~4. Receiving stable maximally tolerated therapy\*at the screening visit \*Maximally tolerated therapy could include a daily statin.~5. Willing and able to comply with clinic visits and study-related procedures~6. Parent(s) or legal guardian(s) must provide the signed informed consent form (ICF). Patients ≥5 years of age (or above age determined by the IRB/EC and in accordance with the local regulations and requirements) must also provide informed assent forms (IAFs) to enroll in the study, and sign and date a separate IAF or ICF signed by the parent(s)/legal guardian(s) (as appropriate based on local regulations and requirements)~Key Exclusion Criteria:~1. Background pharmacologic LMT, nutraceuticals or over-the-counter (OTC) therapies known to affect lipids, at a dose/regimen that has not been stable for at least 4 weeks (8 weeks for PCSK9 inhibitors) before the screening visit and patient is unwilling to enter the run-in period~2. For patients entering Part A, unable to temporarily discontinue apheresis from the baseline visit through the week 4 visit~3. Receiving lipid apheresis, a setting (if applicable) and schedule that has not been stable for approximately 8 weeks before the screening visit or an apheresis schedule that is not anticipated to be stable over the duration of the treatment period (48 weeks).~4. Plasmapheresis within 8 weeks of the screening visit, or plans to undergo plasmapheresis during Part A or Part B~5. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins~6. Newly diagnosed (within 3 months prior to randomization visit) diabetes mellitus or poorly controlled diabetes as defined in the protocol~Note: Other protocol-defined criteria apply

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Evinacumab (Type: EXPERIMENTAL): Part A: Single intravenous (IV) dose Part B: IV dose every 4 weeks (Q4W) until week 20 Part C: IV dose Q4W

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Amyloid documented by biopsy.~2. Documented V30M TTR mutation.~3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status ≥50.~4. Patient is 18-75 years old.~5. If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control. If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, birth control must be used for at least 3 months after the last dose of study medication.~6. Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.~Exclusion Criteria:~1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).~2. Primary amyloidosis.~3. If female, patient is pregnant or breast feeding.~4. Prior liver transplantation.~5. No recordable sensory threshold for vibration perception in both feet, as measured by CASE IV.~6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV).~7. Renal insufficiency or liver function test abnormalities.~8. New York Heart Association (NYHA) Functional Classification ≥III.~9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases).~10. Co-morbidity anticipated to limit survival to less than 18 months.~11. Patient received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1. (Type: EXPERIMENTAL): Fx-1006A
- 2. (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has a diagnosis of palmoplantar pustulosis at screening (participants with concurrent extra-palmoplantar lesions \[includes plaque-type psoriasis lesions\] and/or pustulotic arthro-osteitis \[PAO\] can also be included)~* Participant has active lesions on the palms or soles at screening and baseline~* Participant has inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations and/or phototherapy and/or systemic etretinate prior to or at screening~* Participant has a Palmoplantar Pustulosis Severity Index (PPSI) score of 7 or greater at screening and baseline~* At screening, the results of laboratory blood tests must be within protocol-specified limits~Exclusion Criteria:~* History of or current signs of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurologic, cerebral, or psychiatric disease~* Participant has unstable cardiovascular disease, defined as a recent clinical deterioration in the last 3 months or a cardiac hospitalization within the last 3 months prior to screening~* History of chronic or recurrent infectious disease, including, but not limited to, chronic renal infection, chronic chest infection (eg, bronchiectasis), recurrent urinary tract infection (eg, recurrent pyelonephritis), fungal infection (eg, mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers~* Participant has or has had a serious infection (eg, sepsis, pneumonia or pyelonephritis), or has been hospitalized or received intravenous (IV) antibiotics for an infection during the 2 months prior to screening~* Participant has or has had herpes zoster within the 2 months prior to screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- CNTO 1959 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, at least 18 years of age, with evidence of myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI), in the last week.~Exclusion Criteria:~* Ongoing hemodynamic instability~* Evidence of hepatobiliary disease~* Evidence of chronic kidney disease (CKD) (Stage III, IV, or V), defined as moderate or severe renal impairment or if subject is receiving dialysis~* Evidence of unstable renal function~* History of acute kidney injury after previous exposure to an intravenous contrast agent.~* Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its components~* Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CSL112 - low dose (Type: EXPERIMENTAL): CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
- CSL112 - high dose (Type: EXPERIMENTAL): CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Infusion and Hypoventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I,II~* Age 18-64~* Females undergoing surgical procedures requiring sedation~Exclusion Criteria:~* Pregnant subjects~* Breastfeeding~* Patients or surgeon request~  ---Drop Out:~* Patient or surgeon request,~* Conversion to general anesthesia~* Inability to obtain data from Co2 monitor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): .9 normal saline infusion
- Ketamine (Type: ACTIVE_COMPARATOR): Infusion of ketamine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from patient's legal guardian or legal representative~* 18 - 65 years of age, inclusive~* Head trauma within the last 12 hours~* Traumatic brain injury with Glasgow Coma Score (GCS) ≥ 5 and that requires ICP monitoring~* Catheter placement for monitoring and management of increased ICP~* Microdialysis probe placement in penumbra zone or ipsilateral to contusion if focal~* Systolic blood pressure ≥ 100 mmHg~* Females of child-bearing potential must have a negative pregnancy test~Exclusion Criteria:~* Penetrating head injury (e.g. missile, stab wound)~* Not expected to survive more than 24 hours after admission~* Concurrent, but not pre-existing, spinal cord injury~* Unilateral and bilateral fixed and dilated pupil (\> 4 mm)~* Cardiopulmonary resuscitation performed post injury~* continuing bleeding likely to require multiple transfusions (\> 4 units red blood cells)~* Coma due to a pure epidural hematoma (lucid interval and absence of structural brain damage on CT scan)~* Coma suspected to be primarily due to other causes than head injury (e.g. drug overdose)~* Known or CT scan evidence of pre-existing major cerebral damage~* Decompressive craniectomy, planned prior to randomization~* Polytraumatic patients with Injury Severity Score \> 25, or rhabdomyolysis~* Injuries to ascending aorta and/or carotid arteries~* serum creatinine values \> 1.5 mg/dL~* estimated Glomerular Filtration Rate \< 60 ml/min (MDRD-formula)~* body mass index (BMI) \> 35, Body weight \> 120 kg~* Any severe concomitant condition (cancer; hematologic, renal, hepatic, coronary disease; major psychiatric disorder; alcohol or drug abuse), that can be ascertained at admission~* Known to have received an experimental drug within 4 weeks prior to current injury~* Administration of \> 100 ml of contrast media containing iodine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VAS203 15 mg/kg (Type: EXPERIMENTAL): Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
- VAS203 20 mg/kg (Type: EXPERIMENTAL): 10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
- VAS203 30 mg/kg (Type: EXPERIMENTAL): 10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
- Saline (Type: PLACEBO_COMPARATOR): 0.9 % Sodium chloride infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete